Alemtuzumab vs. Interferon Beta-1a in Early Multiple Sclerosis
NEJM 359:1786-1801,1838, The CAMMS223 Trial Investigators, 2008
Alemtuzumab for Multiples Sclerosis: Who and When to treat?
Lancet 380:1795-1797, 1792, Springer, T. & Kappos, L., 2012
Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis
JAMA 32:165-174,153, Burt, R.K.,et al, 2019
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Severe Relapses under Fingolimod Treatment Prescribed after Natalizumab
Neurol 79:2004-2006,1942, Centonze, D.,et al, 2012
Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis
NEJM 365:1293-1303, OConnor, P.,et al, 2011
A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
NEJM 362:416-426, 456, Giovannoni,G.,et al, 2010
Relapse Management in Multiple Sclerosis
The Neurologist 15:1-5, Thrower,B.W., 2009
Reduction of Disease Activity and Disability With High-Dose Cyclophosphamide in Patients With Aggressive Multiple Sclerosis
Arch Neurol 65:1044-1051, Krishnan,C.,et al., 2008
Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006
A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006
Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis
NEJM 355:1124-1140, Kappos,L.,et al, 2006
Mitoxantrone for Multiple Sclerosis in Clinical Practice
Neurol 63(Suppl 6):S25-S27, Rizvi,S.A.,et al, 2004
Intravenous Immunoglobulin Treatment in Multiple Sclerosis, Effect on Relapses
Neurol 50:398-402, Achiron,A.,et al, 1998
Intravenous Immunoglobulin G Reduces MRI Activity in Relapsing Multiple Sclerosis
Neurol 50:1273-1281, Sorensen,P.S.,et al, 1998
Randomised Placebo-Controlled Trial of Monthly IVIg Therapy in Relapsing-Remitting MS
Lancet 349:589-593, 5861997., Fazekas,F.,et al, 1997
Management of Multiple Sclerosis
NEJM 337:1604-1611, Rudick,R.A.,et al, 1997
Linomide Reduces the Rate of Active Lesions in Relapsing-Remitting Multiple Sclerosis
Neurol 47:895-900, Anderson,O.,et al, 1996
Open Controlled Therapeutic Trial of Intravenous Immune Globulin in Relapsing-Remitting Multiple Sclerosis
Arch Neurol 49:1233-1236, Achiron,A.,et al, 1992
The Efficacy of Azathiorpine in Relapsing-Remitting Multiple Sclerosis
Neurol 41:20-25, Goodkin,D.E.,et al, 1991
Overview of Azathioprine Treatment in Multiple Sclerosis
Lancet 338:1051-1055, Yudkin,P.L.,et al, 1991
Severely Threatening Events and Marked Life Difficulties Preceding Onset or Exacerbation of MS
JNNP 52:8-13, Grant,I.,et al, 1989
Double-Blind Study of True vs. Sham Plasma Exchange in Patients Treated with Immunosuppression for Acute Attacks of MS
Neurol 39:1143-1149, Weiner,H.L.,et al, 1989